FY2025 · ended Dec 31, 2025 · Revenue $149.16M, +99.2% YoY · Filed Mar 17, 2026
Neuronetics, Inc. (STIM) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $149.2 million and a net loss of $39.0 million. Free cash flow was -$21.2 million. As of Sep 30, 2026 it held $22.1 million in cash and investments and $87.7 million in total debt.
Revenue (TTM)
$159.76M
+23.0% vs year-ago TTM
Net income (TTM)
$-23.08M
+48.1% vs year-ago TTM
Operating cash flow (TTM)
$-8.31M
+72.2% vs year-ago TTM
Free cash flow (TTM)
$-9.61M
+68.5% vs year-ago TTM
EPS (TTM)
$-0.32
+58.3% vs year-ago TTM
Dividend per share
None
Shares outstanding
69.28M
+5.3% vs prior year
Net cash
$-65.62M
as of Sep 30, 2026
Operating margin
-9.4%
FY 2026
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- STIM (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Malvern, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1227636
- Former names
- Neuronetics, Inc. (until Nov 4, 2026); NEURONETICS INC (until Aug 16, 2006)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $149.2M | $74.9M | $71.3M | $65.2M | $55.3M |
| Operating income | -$31.4M | -$34.6M | -$30.6M | -$35.1M | -$27.6M |
| Net income | -$39.0M | -$43.7M | -$30.2M | -$37.2M | -$31.2M |
| Diluted EPS | -$0.59 | -$1.38 | -$1.05 | -$1.38 | -$1.22 |
| Operating cash flow | -$20.4M | -$31.0M | -$32.0M | -$30.7M | -$28.0M |
| Free cash flow | -$21.2M | -$32.5M | -$34.4M | -$34.0M | -$30.3M |
| Total assets | $141.6M | $140.9M | $115.8M | $116.9M | $141.2M |
| Total liabilities | $115.3M | $109.1M | $81.6M | $59.8M | $56.0M |
| Stockholders' equity | $22.4M | $27.7M | $34.2M | $57.1M | $85.2M |
| Cash and investments | $28.1M | $18.5M | $59.7M | $70.3M | $94.1M |
| Total debt | $90.3M | $82.6M | $62.5M | $39.7M | $39.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 17, 2026 | Aug 11, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jul 20, 2026 | Jul 9, 2026 |
All 719 Neuronetics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.